Skip to main content

Table 2 LETM initial treatment

From: Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies

 

This cohort

Delay of treatment after first symptoms (mean, days)

10

First line of treatment (n = 53/53)

 Infusions of methylprednisolone

52 (98%)

Second line of treatment (n = 24/53)

 Plasmapheresis

17 (71%)

 Infusions of methylprednisolone

5 (21%)

 IV immunoglobulins

2 (8%)

Third line of treatment (n = 4/53)

 Infusions of methylprednisolone

2 (50%)

 Plasmapheresis

2 (50%)

Relay by oral steroids (n = 23/53)

 Duration (data for 15 patients) months

7.2 (0.2–12)

  1. LETM longitudinal extensive transverse myelitis, IV intravenous